IKT

2.33

3.32% -0.08

Dopo l'orario di chiusura: 2.33

Inhibikase Therapeutics Inc (IKT)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.41

Aprire:

$2.37

Volume 24 ore:

332.37K

Relative Volume:

0.45

Capitalizzazione di mercato:

$325.12M

Reddito:

$79,600

Utile/perdita netta:

$-48.26M

Rapporto P/E:

-4.7338

EPS:

-0.4922

Flusso di cassa netto:

$-28.24M

1 W Prestazione:

-7.54%

1M Prestazione:

-5.28%

6M Prestazione:

+19.49%

1 anno Prestazione:

+51.30%

Intervallo 1D:

$2.32

$2.385

Intervallo di 1 settimana:

$2.32

$2.55

Portata 52W:

$1.33

$2.61

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Nome

Inhibikase Therapeutics Inc

Settore

Healthcare (1069)

Industria

Biotechnology (595)

Telefono

(302) 295-3800

Indirizzo

1000 N. WEST STREET, SUITE 1200, WILMINGTON

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-13

Ultimi documenti SEC

IKT's Discussions on Twitter

Compare IKT vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IKT Inhibikase Therapeutics Inc	2.33	336.28M	79,600	-48.26M	-28.24M	-0.4922
VRTX Vertex Pharmaceuticals Inc	514.56	132.08B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	793.26	83.15B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	984.04	62.71B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	136.62	54.14B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.35	44.51B	742.00K	-1.37B	-1.07B	-7.0731

Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-04	Iniziato	Ladenburg Thalmann	Buy
2026-01-21	Iniziato	BofA Securities	Buy
2025-12-26	Iniziato	H.C. Wainwright	Buy
2025-12-11	Iniziato	Cantor Fitzgerald	Overweight
2025-02-12	Downgrade	H.C. Wainwright	Buy → Neutral

Inhibikase Therapeutics Inc Borsa (IKT) Ultime notizie

Sep 08, 2026

Inhibikase advances IKT-001 in pivotal PAH Phase 3 - TipRanks

Sep 08, 2026

Inhibikase updates corporate presentation, highlights Phase 3 IKT-001 program and timelines - TradingView

Sep 08, 2026

Inhibikase (NASDAQ: IKT) tests PAH pill in pivotal global trial - Stock Titan

Sep 08, 2026

Sep 04, 2026

IKT News | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill

Sep 04, 2026

Sep 03, 2026

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Sep 03, 2026

Sep 01, 2026

Inhibikase Therapeutics (NASDAQ:IKT) Stock Price Down 4.1%What's Next? - MarketBeat

Sep 01, 2026

Aug 26, 2026

Inhibikase Therapeutics Appoints Deloitte & Touche LLP After Dismissing CohnReznick LLP as Auditor - Kalkine Media

Aug 26, 2026

Aug 21, 2026

Inhibikase (IKT) Chart: Adds 1.70% to Close at $2.39 in Latest Trading; Trading Range: the Supplied Trading Band Runs From $2.27 to $2.51 for the Current SessionFibonacci Extension - siam.in

Aug 21, 2026

Aug 19, 2026

Inhibikase (IKT) Q1 2026 Results: EPS Prints Above Forecast; Post-Earnings: Shares Finish 0.42% Higher at the CloseFree Cash Flow Trends - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Inhibikase Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 18, 2026

Inhibikase Loss Widens as Phase 3 PAH Trial Expands - MyChesCo

Aug 18, 2026

Aug 17, 2026

Inhibikase Therapeutics (IKT) Slips 1.5% as Shares Test Support at $2.25Shakeout Pattern - vinanet.vn

Aug 17, 2026

Aug 16, 2026

Inhibikase Therapeutics (IKT) Holds Steady at $2.41 as Shares Consolidate Between $2.29 Support and $2.53 ResistanceReversal Setup Alerts - vinanet.vn

Aug 16, 2026

IKT Q1 2026 Earnings: Narrower Loss of $0.10 Per Share Beats Estimates as Pre-Revenue Biotech Holds SteadyEPS Surprise History - vinanet.vn

Aug 16, 2026

Aug 14, 2026

Perceptive group (IKT) discloses 6.9% Inhibikase stake through 10.3M warrant shares - Stock Titan

Aug 14, 2026

Nantahala reports 4.30% Inhibikase (IKT) stake across 5.81M shares - Stock Titan

Aug 14, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 14, 2026

IKT Q1 2026 Earnings: Narrower-than-Expected Loss Despite Modest Share PullbackNegative Surprise Momentum - vinanet.vn

Aug 14, 2026

Aug 13, 2026

Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants - Stock Titan

Aug 13, 2026

Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 13, 2026

Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth - TipRanks

Aug 13, 2026

Aug 12, 2026

Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026

Aug 11, 2026

Is Inhibikase Therapeutics Inc (IKT) Positioned for Growth After Reporting $0.11 Loss? GF Score: 36/100 - GuruFocus

Aug 11, 2026

LifeSci Capital Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 11, 2026

Inhibikase grants $2.03 stock options to seven new hires - scanx.trade

Aug 11, 2026

Inhibikase Q2 EPS of $(0.11) meets analyst consensus estimates - scanx.trade

Aug 11, 2026

Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 11, 2026

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - Yahoo Finance

Aug 11, 2026

Aug 10, 2026

Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 09, 2026

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Aug 09, 2026

Aug 02, 2026

Perceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT - MarketBeat

Aug 02, 2026

Aug 01, 2026

Inhibikase Therapeutics (IKT) Declines 4.4% as Stock Pressures Key $2.07 Support ZoneBreadth Thrust - dars.gov.et

Aug 01, 2026

Inhibikase Therapeutics (IKT) Slides 4.4% to $2.18 as Biotech Stock Presses Toward Key SupportEarly Entry Signals - vinanet.vn

Aug 01, 2026

Jul 31, 2026

Inhibikase Therapeutics, Inc. Revenue Breakdown – NASDAQ:IKT - TradingView

Jul 31, 2026

Inhibikase Wins FDA Orphan Status for PAH Drug Candidate - MyChesCo

Jul 31, 2026

18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT) - Stock Titan

Jul 31, 2026

H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status - Investing.com Canada

Jul 31, 2026

Jul 29, 2026

Inhibikase Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Continues - dars.gov.et

Jul 29, 2026

IKT Q1 2026 Earnings: Narrower-than-Expected Loss per Share; Shares Slide 4.3%Profit Cycle Analysis - vinanet.vn

Jul 29, 2026

Jul 28, 2026

Inhibikase Therapeutics (IKT) Slips 1% as Shares Test Key Support at $2.21RVOL Breakout - dars.gov.et

Jul 28, 2026

Jul 27, 2026